Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Merck
Johnson and Johnson
Harvard Business School
Mallinckrodt

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,753,646

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,753,646 protect, and when does it expire?

Patent 5,753,646 protects APTIOM and is included in one NDA.

This patent has twenty-seven patent family members in twenty countries.

Summary for Patent: 5,753,646
Title: Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
Abstract:New compounds of general formula I, including all possible stereoisomers, are described ##STR1## wherein: R is hydrogen, alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group. A process for their preparation consists of reaction of compound II ##STR2## with an acylating agent.
Inventor(s): Benes; Jan (Oporto, PT), Soares Da Silva; Patricio M. V. A. (Oporto, PT)
Assignee: Portela & Ca., S.A. (Oporto, PT)
Application Number:08/673,819
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,753,646
Patent Claim Types:
see list of patent claims
Compound; Process; Use; Composition;

Drugs Protected by US Patent 5,753,646

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
Sunovion Pharms Inc APTIOM eslicarbazepine acetate TABLET;ORAL 022416-004 Nov 8, 2013 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,753,646

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Portugal101732Jun 30, 1995

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Boehringer Ingelheim
McKesson
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.